Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
13 pending office actions • 13 clients • 13 examiners • 9 art units • 0 of 13 (0%) have an AI response strategy ready
Houston Beshining Law Office PLLC maintains a specialized practice in the Biotechnology & Pharmaceuticals technology area. With 275 career applications, the firm demonstrates experience in handling the complex regulatory and technical requirements of this sector. Its resolved allowance rate pct of 71.05 provides a clear metric for its historical success in securing patent grants for its clients. This rate reflects the firm's ability to navigate the rigorous examination standards common in life sciences.
The firm currently manages 9 pending office actions, indicating its ongoing engagement with the patent office. On average, the firm receives 2.54 avg office actions per allowance. This figure suggests the level of persistence and negotiation required to move an application from filing to issuance. For practitioners, the 71.05 resolved allowance rate pct and 2.54 avg office actions per allowance serve as key indicators of the firm's prosecution efficiency and effectiveness in the Biotechnology & Pharmaceuticals field. These metrics help set expectations for the timeline and likelihood of success for the 275 career applications handled by the firm.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (31%) |
| §102 only | 1 (8%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 3 (23%) |
| Multi-statute (no §101) | 4 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.5% | +8.0% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| OTTON, ALICIA L | 1 | 64.9% | +9.4% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| STOCKTON, LAURA LYNNE | 1 | 75.2% | +33.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482835 | NOSE-TO-BRAIN DELIVERY FORMULATION OF NIMODIPINE, PREPARATION AND USE | FOWLER, ALAN JEROME | 21d |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | HABTE, KAHSAY | 62d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785041 | NEODYMIUM-IRON-BORON MAGNET MATERIAL, RAW MATERIAL COMPOSITION PREPARATION METHOD THEREFOR AND USE THEREOF | O'KEEFE, SEAN P | 26d |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | — |
| 18729910 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | OTTON, ALICIA L | — |
| 18684856 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | — |
| 18248867 | SUBLINGUAL FILM DOSAGE OF RASAGILINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WISTNER, SARAH CLINKSCALES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | FETTEROLF, BRANDON J | 16d overdue |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | — |
| 18419536 | ORAL RETENTION DEVICE AND OSMOTIC PUMP TABLET, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SASAN, ARADHANA | — |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | BREDEFELD, RACHAEL EVA | — |
| 18254186 | SALT OF PYRROLOPYRIMIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND APPLICATION THEREOF | STOCKTON, LAURA LYNNE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1622 | 1 |
| 3783 | 1 |
| 1691 | 1 |
| 3786 | 1 |
| 1624 | 1 |
| 1616 | 1 |
| 3799 | 1 |
| 1738 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18862180 | FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 | Scibrunch Therapeutics Co., Ltd. | SEAMAN, D MARGARET M | §102 | Non-Final OA | — | Pending | Nov 01, 2024 | |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | KWON, YONG SOK | §112DP | Non-Final OA | — | Pending | Sep 04, 2024 | |
| 18729910 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Center For Excellence In Molecular Cell Science, Chinese Academy Of Sciences | OTTON, ALICIA L | §102§112 | Non-Final OA | — | Pending | Jul 18, 2024 | |
| 18684856 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Best-Link Bioscience, LLC | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18419536 | ORAL RETENTION DEVICE AND OSMOTIC PUMP TABLET, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Wd Pharmaceutical Co., Ltd. | SASAN, ARADHANA | 3783 | §103§112DP | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18482835 | NOSE-TO-BRAIN DELIVERY FORMULATION OF NIMODIPINE, PREPARATION AND USE | Nasal-Phyto (Shanghai) Pharmaceutical Technology Co., Ltd. | FOWLER, ALAN JEROME | 1691 | §103 | Final Rejection | 21d | Pending | Oct 06, 2023 |
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | Medshine Discovery Inc. | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 16d overdue | Pending | Sep 14, 2023 |
| 18549186 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | BREDEFELD, RACHAEL EVA | 3786 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18263702 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Breakthrough Pharmaceuticals Inc. | HABTE, KAHSAY | 1624 | §103 | Non-Final OA | 62d | Pending | Jul 31, 2023 |
| 18254186 | SALT OF PYRROLOPYRIMIDINE COMPOUND, CRYSTALLINE FORM THEREOF, AND APPLICATION THEREOF | Guangzhou Joyo Pharmatech Co., Ltd. | STOCKTON, LAURA LYNNE | 1626 | §102§112DP | Non-Final OA | — | Pending | May 24, 2023 |
| 18248867 | SUBLINGUAL FILM DOSAGE OF RASAGILINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Modern Pharmaceutical Engineering Research Center Co., Ltd. | WISTNER, SARAH CLINKSCALES | 1616 | §103§112 | Final Rejection | — | Pending | Apr 12, 2023 |
| 18005963 | BIONIC TISSUE STENT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sinobioprint (Shanghai) Biotech Ltd. | PELLEGRINO, BRIAN E | 3799 | §103 | Final Rejection | — | Pending | Jan 18, 2023 |
| 17785041 | NEODYMIUM-IRON-BORON MAGNET MATERIAL, RAW MATERIAL COMPOSITION PREPARATION METHOD THEREFOR AND USE THEREOF | Fujian Golden Dragon Rare-Earth Co., Ltd. | O'KEEFE, SEAN P | 1738 | §103§112 | Non-Final OA | 26d | Pending | Jun 13, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial